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Apolipoprotein E is associated with age-related risk
for Alzheimer’s disease and plays critical roles in Ab
homeostasis. We report that ApoE plays a role in facil-
itating the proteolytic clearance of soluble Ab from
the brain. The endolytic degradation of Ab peptides
within microglia by neprilysin and related enzymes
is dramatically enhanced by ApoE. Similarly, Ab deg-
radation extracellularly by insulin-degrading enzyme
is facilitated by ApoE. The capacity of ApoE to pro-
mote Ab degradation is dependent upon the ApoE
isoform and its lipidation status. The enhanced ex-
pression of lipidated ApoE, through the activation of
liver X receptors, stimulates Ab degradation. Indeed,
aged Tg2576 mice treated with the LXR agonist
GW3965 exhibited a dramatic reduction in brain Ab
load. GW3965 treatment also reversed contextual
memory deficits. These data demonstrate a mecha-
nism through which ApoE facilitates the clearance
of Ab from the brain and suggest that LXR agonists
may represent a novel therapy for AD.
INTRODUCTION
Alzheimer’s disease (AD) is characterized by the accumulation
and deposition of Ab peptides within the brain, leading to the
perturbation of synaptic function and neuronal loss that typifies
the disease (Tanzi and Bertram, 2005). Genetic analysis of famil-
ial forms of AD has established the centrality of APP processing
and Ab production to disease pathogenesis. Ab peptides are
normally produced by neurons in the brain and cleared through
efflux into the peripheral circulation (Zlokovic et al., 2005) and
through their degradation by proteinases within the brain (Hardy
and Selkoe, 2002).
An isoform of apolipoprotein E, ApoE4, has been shown to
confer dramatically increased risk for late-onset AD (LOAD)(Roses et al., 1995); however, the basis for this remains one of
the major unanswered questions of disease pathogenesis.
ApoE plays critical roles in regulating brain Ab peptide levels,
as well as their deposition and clearance (Holtzman, 2001; Zlo-
kovic et al., 2005). Thus, processes that regulate ApoE expres-
sion and functional state could affect its ability to influence brain
Ab homeostasis. ApoE is the predominant apolipoprotein in the
brain and is synthesized and secreted mainly by astrocytes
(but also by microglia; Xu et al., 2006, 2000) within unilamellar
HDL-like particles (Fagan et al., 1999). ApoE is lipidated princi-
pally through the action of the ATP-binding cassette transporter
ABCA1 (and related transporters), which acts in a variety of cell
types to transfer both phospholipids and cholesterol to ApoE
(Hirsch-Reinshagen et al., 2004; Wahrle et al., 2004), and, in
this way, ApoE acts to traffic lipids throughout the brain. The lip-
idation status of ApoE is an important functional parameter, gov-
erning its conformation (Fisher and Ryan, 1999), intrinsic stability
(Hirsch-Reinshagen et al., 2004; Wahrle et al., 2004), and interac-
tions with membrane receptors (Dergunov et al., 2000; Ladu
et al., 2006). Importantly, ApoE binds to Ab, and this, too, is influ-
enced by its lipidation status (Tokuda et al., 2000). Studies with
APP transgenic mice have demonstrated ApoE isoform-specific
effects on the propensity of Ab to be deposited in the brain (E4 >
E3 > E2), the nature of the deposits, and a gene-dosage-related
influence on the magnitude of these effects (Holtzman, 2004).
ApoE lipidation status is also a significant determinant of
whether its interaction with Ab leads to efflux of the peptides
from the brain or, alternatively, to the formation of fibrils and their
deposition into plaques (Bell et al., 2007; LaDu et al., 1995; Mor-
ikawa et al., 2005; Tokuda et al., 2000). Recently, three indepen-
dent studies have reported that inactivation of the Abca1 gene in
APP-expressing transgenic mice resulted in reduced levels of
ApoE. Remarkably, these mice exhibited a seemingly paradoxi-
cal elevation of brain Ab peptide levels and a doubling of Ab
plaque burden without a significant effect on Ab generation
(Hirsch-Reinshagen et al., 2005; Koldamova et al., 2005a;
Wahrle et al., 2005). The outcomes of these studies strongly sug-
gested that lipidated forms of ApoE act to enhance the clearance
of Ab peptides from the brain. The aim of the present study wasNeuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc. 681
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affect Ab homeostasis.
Liver X receptors (LXRs) are ligand-activated transcription fac-
tors that induce the expression of Apoe, Abca1, and other genes
of lipid metabolism (Beaven and Tontonoz, 2006). LXRs act
physiologically as cellular cholesterol sensors and are activated
by oxysterols. There are two LXR isoforms, LXRa and LXRb
(encoded by Nrlh3 and Nrlh2, respectively), both of which are
expressed in the brain (Wang et al., 2002), and their activation
results in the rapid and robust increase in the levels of lipidated
forms of ApoE (Cao et al., 2007; Jiang et al., 2003; Liang et al.,
2004). Thus, regulation of LXR transcriptional activity provides
a mechanism to regulate brain ApoE levels and its lipidation
status.
The brain possesses robust intrinsic Ab clearance mecha-
nisms (Tanzi et al., 2004). Ab peptides are proteolytically de-
graded within the brain principally by neprilysin (NEP) (Iwata
et al., 2000) and insulin-degrading enzyme (IDE, insulysin) (Kur-
ochkin and Goto, 1994). Genetic inactivation of these genes (Far-
ris et al., 2003; Iwata et al., 2001) or administration of inhibitors of
these proteinases into the brain results in substantial elevation of
Ab levels in the brain and induction of plaque deposition (Dolev
and Michaelson, 2004). Conversely, overexpression of IDE or ne-
prilysin lowered brain Ab levels and reduced plaque formation
(Hemming et al., 2007; Leissring et al., 2003). It has been argued
that the predominant mode of Ab42 clearance from the brain is
through its proteolytic degradation because this peptide is not
efficiently exported through the vasculature (Deane et al.,
2004). Microglia, the brain’s resident macrophages, play an
essential role in Ab clearance through their ability to take up
and degrade soluble and fibrillar forms of Ab (Rogers et al.,
2002). Moreover, both microglia and astrocytes secrete protein-
ases, including IDE, that mediate the degradation of Ab peptides
in the extracellular milieu (Qiu et al., 1998).
Despite considerable effort, the cellular mechanisms through
which ApoE influences Ab clearance remain unresolved. We re-
port that ApoE acts to facilitate the proteolytic degradation of Ab,
a previously unappreciated action of this apolipoprotein. More-
over, the lipidation status of ApoE is a critical determinant of its
ability to stimulate Ab degradation, and this finding provides
a mechanistic explanation of the increased Ab levels and depo-
sition observed in APP-expressing mice lacking the Abca1 gene.
Importantly, we demonstrate that elevation of lipidated forms of
ApoE, through activation of LXRs, results in reduced Ab peptide
and plaque levels in an animal model of AD and is associated
with improved contextual memory. Therapeutic agents that
increase the abundance of highly lipidated forms of ApoE,
including LXR agonists, may attenuate disease pathogenesis
and represent a promising strategy for the treatment of AD.
RESULTS
Microglia Efficiently Take Up and Degrade Soluble Ab
We first investigated the contribution of microglia to the clear-
ance of soluble Ab. We found that these cells rapidly take up sol-
uble forms of Ab from the extracellular milieu (Figure 1A) through
a nonsaturable (Figure 1B) macropinocytotic uptake mechanism
(S.M. et al., unpublished data). The internalized Ab is rapidly traf-682 Neuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc.ficked to a late endosomal/lysosomal compartment (Figure 1C).
Indeed, incubation of BV-2 microglia with soluble Ab42 resulted
in the loss of Ab from the medium, with complete clearance of the
peptide within 24 hr (Figure 1D) that is reflective of both of its
uptake into microglia as well as degradation by proteinases
secreted by these cells into the extracellular milieu. Microglia
efficiently degrade internalized soluble Ab, and we observed little
or no resecretion of Ab into the medium (Figure 1E). The intracel-
lular degradation of Ab by microglia is carried out principally by
neprilysin and related proteases whose activity can be inhibited
by phosphoramidon and thiorphan (Iwata et al., 2000; Tanzi
et al., 2004), because in the presence of these protease inhibitors
the degradation of internalized soluble Ab was dramatically
inhibited (Figure 1F).
HDL Apolipoproteins Enhance the Cellular Degradation
of Soluble Ab by Microglia
ApoE has been postulated to facilitate the clearance of Ab pep-
tides from the brain, and we tested whether ApoE and related
apolipoproteins influenced the ability of microglia to degrade sol-
uble Ab. ApoA-I is another major HDL-associated apolipoprotein
both in the periphery and in the brain (Koch et al., 2001). Impor-
tantly, it functions and is trafficked in a manner similar to ApoE
(Smith et al., 2004; Wang et al., 2001). ApoA-I is also lipidated
by ABCA1 (Denis et al., 2004) and avidly binds Ab peptides
(Harr et al., 1996; Koldamova et al., 2001), thus providing an
independent measure of HDL apolipoprotein function. BV-2
microglia (Figure 2A) or primary microglia (Figure 2B) were incu-
bated with soluble Ab42 in the presence of exogenously supplied
ApoE or ApoA-I. Coincubation with purified human ApoE or
ApoA-I resulted in a dramatic stimulation of Ab clearance from
the microglia. ApoE and ApoA-I elicited a similar reduction in in-
tracellular Ab levels, demonstrating that the observed effects are
reflective of the common actions of these apolipoproteins. The
effect of ApoE on microglial Ab clearance is dose dependent
(Figure 2C). We measured the efficiency with which ApoE stimu-
lated the clearance of Ab from microglia by monitoring, in paral-
lel, both the cumulative uptake of Ab using fluorescently labeled
Ab42 and the intracellular levels of the intact Ab42 peptide by
ELISA (Figures 2D–2F). Fluorescently labeled Ab is taken up by
microglia and degraded; however, the fluorophore is retained
within the cells, and the total cellular fluorescence is an indepen-
dent measurement of total Ab uptake (S.M. et al., unpublished
data). We found that the ApoE-stimulated reduction in intracellu-
lar Ab levels was a consequence of enhanced degradation and
was observed at both 3 and 9 hr of incubation. These data dem-
onstrate that the degradation of soluble Ab within microglia is
significantly enhanced by HDL apolipoproteins.
Activation of LXR increased the expression of ApoE and
ABCA1 (Burns et al., 2006; Koldamova et al., 2003; Sun et al.,
2003), resulting in elevated levels of lipidated ApoE in astrocytes
(see Figures S1A and S1B available online). Microglia express
both LXR isoforms and respond to LXR agonists (Zelcer et al.,
2007). These cells also express and secrete lipidated forms of
ApoE (Xu et al., 2000). We tested whether elevation of lipidated
ApoE levels would result in enhanced Ab degradation by micro-
glia by treating these cells with an agonist of LXRs. BV-2 micro-
glia (Figure 3A) or primary microglia (Figure 3B) were pretreated
Neuron
ApoE Promotes the Proteolytic Degradation of AbFigure 1. Microglia Efficiently Take Up and Degrade Soluble Ab
(A) Kinetics of soluble Ab uptake by microglia. BV2 microglia were incubated with exogenous Alexa 488-labeled soluble Ab42 for the indicated periods. The
uptake of fluorescently labeled soluble Ab was measured using flow cytometry.
(B) Soluble Ab is dose-dependently taken up by microglia. BV2 microglia were incubated for 3 hr with the indicated concentrations of unmodified soluble Ab42.
The intracellular Ab42 levels were measured using ELISA. The results were normalized to total cellular protein.
(C) Soluble Ab is rapidly trafficked to lysosomes for degradation. Confocal imaging of live BV-2 microglia 15 min after addition of 2 mg/ml soluble Cy3-Ab42
demonstrated localization of Ab (red) within lysosomes. Lysosomes were stained using LysoTracker (green).
(D) Exogenous soluble Abwas efficiently cleared from the medium by microglia. BV2 microglia were incubated with 2 mg/ml Ab42 for the indicated time. The media
were collected and immunoblotted for Ab (mean ± SEM, ***p < 0.001, ###p < 0.001).
(E) Soluble Ab can be degraded by microglia. BV2 microglia were incubated for 3 hr with 2 mg/ml unmodified soluble Ab42. After washout of the remaining Ab42 in
the media, the intracellular Ab42 levels were measured using ELISA. The media were also monitored for resecreted Ab.
(F) Neprilysin and related proteinases mediate intracellular degradation of soluble Ab by microglia. Primary microglia from wild-type mice were pretreated with
vehicle, 10 mM phosphoramidon or 1 mM thiorphan for 18 hr. The cells were then incubated with 2 mg/ml Ab42 in the presence of vehicle or drug for an additional
24 hr. The data represent the outcome of three independent experiments (mean ± SEM, *p < 0.05).with the LXR-specific agonist GW3965 for 18 hr and then incu-
bated with exogenous soluble Ab42 for an additional 3 or 24 hr,
respectively. The GW3965-treated microglia exhibited signifi-
cantly lower levels of intracellular Ab42 due to the enhanced deg-
radation of Ab in the drug-treated cells compared to vehicle-
treated controls. Similar effects were observed using another
LXR agonist, T0901317 (Figure 3C). LXR activation was verified
by the observation of increased expression of its target gene
products: ABCA1 and ApoE (Figures 3A and 3B). Significantly,
the combined treatment with both the LXR agonist and provision
of exogenous HDL apolipoproteins resulted in a further reduction
of intracellular Ab levels, evaluated either by western analysis
(Figures 3A and 3B) or by ELISA (Figure 3C). Control experiments
established that the uptake of soluble Ab was not affected by
the presence of either exogenous ApoA-I or the LXR activation
agonist (Figure S2A). LXR activation did not affect the expression
of neprilysin in microglia (Figure S3). These data suggest that
LXR activation facilitates the degradation of Ab peptides, and
this is associated with induction of LXR target genes, including
Abca1 and Apoe, and elevation of lipidated ApoE levels.
ApoE Is Essential for Efficient Intracellular Degradation
of Soluble Ab by Microglia
To directly assess whether ApoE was essential for efficient intra-
cellular Ab degradation, wild-type orApoe/microglia were iso-lated and incubated with soluble Ab42. Loss of Apoe does not
impair soluble Ab uptake by microglia (Figure S2C). Wild-type
microglia efficiently degrade Ab, resulting in lower cellular Ab
levels when examined 24 hr later. However, the degradation of
soluble Ab by Apoe-deficient microglia was significantly im-
paired (Figures 4A and 4B). When the Apoe null microglia were
provided with exogenous ApoE (Figure 4C), their ability to
efficiently degrade soluble Ab was restored, verifying that intra-
cellular Ab degradation is facilitated by ApoE. Treatment of
Apoe-deficient microglia with GW3965 was without effect, dem-
onstrating the that effect of LXR agonists on Ab degradation is
dependent on expression of ApoE (Figure 4D).
Human ApoE isoforms confer different risk for LOAD (E4 > E3 >
E2) (Roses et al., 1995). We investigated whether the individual
ApoE isoforms differ in their ability to facilitate the proteolytic
degradation of soluble Ab by microglia. We isolated ApoE-
containing HDL particles produced by immortalized astrocytes
derived from mice in which human APOE2, -E3, or -E4 alleles
were knocked into endogenous mouse Apoe locus (Morikawa
et al., 2005). Primary microglia from Apoe/ animals were
treated with Ab42 in the absence or the presence of the same
amount of purified human ApoE-containing HDL particles. While
all isoforms of human ApoE increased clearance of soluble Ab,
ApoE2 exhibited the strongest effect, whereas ApoE4 was signif-
icantly less efficient in promoting the degradation of soluble AbNeuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc. 683
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BV2 microglia (A) or primary microglia from wild-type mice (B) were incubated with 2 mg/ml Ab42 in the presence or absence of 20 mg/ml ApoA-I or 5 mg/ml ApoE
for 3 hr or 24 hr, respectively. The intracellular Ab42 levels were quantified from three independent experiments and data normalized to loading controls. Values
are expressed as percentage relative to the value of controls (mean ± SEM, **p < 0.01, ***p < 0.001). (C) ApoE dose-dependently increased Ab degradation in
microglia. BV2 microglia were incubated with 2 mg/ml Ab42 in the presence of increasing concentrations of purified human ApoE (0, 0.2, 1, or 5 mg/ml) for 3 hr,
intracellular Ab42 levels were quantified using ELISA, and data normalized to total protein (mean ± SEM, *p < 0.05). (D–F) ApoE enhanced soluble Ab degradation.
BV2 microglia were incubated with 2 mg/ml Ab42 or 2 mg/ml Alexa 488-labeled Ab42 in the presence or absence of 1 mg/ml purified human ApoE for indicated time.
(D) The remaining intracellular Ab42 levels were quantified using ELISA and data normalized to total protein (mean ± SEM, ***p < 0.001). (E) The total internalized
Ab42 over the same intervals was monitored using flow cytometry. (F) The efficiency of Ab degradation was expressed as a ratio of remaining intact Ab42 over
total internalized Ab42 (mean ± SEM, ***p < 0.001).(Figure 4E). Addition of ApoE particles did not significantly influ-
ence the uptake of soluble Ab by Apoe/ microglia. These data
demonstrate an ApoE isoform-specific promotion of the proteo-
lytic degradation of soluble Ab that is consistent with the linkage
of these isoforms to disease risk.
The Lipidation Status of ApoE Influences Its Ability
to Promote the Intracellular Degradation of Soluble Ab
The degree of ApoE lipidation and HDL particle size are gov-
erned primarily by the expression level of ABCA1 (Figures S1A,
S1D, S1F, and S1G) which, in turn, is directly regulated by
LXRs (Figure S1A) (Lee and Parks, 2005). We investigated
whether ABCA1 affects the ability of ApoE to facilitate the
proteolytic degradation of soluble Ab by microglia. We isolated
primary microglia from Abca1/, Abca1+/, and wild-type
mice and compared their ability to degrade exogenously sup-
plied soluble Ab. The Abca1 genotype did not significantly influ-
ence the uptake of soluble Ab by microglia (Figure S2C). Micro-
glia expressing Abca1 were able to efficiently degrade soluble
Ab. However, Abca1 null microglia, which cannot efficiently lipi-
date ApoE, exhibited significantly higher intracellular Ab levels,
reflecting their impaired ability to degrade the soluble Ab pep-
tides (Figure 5A). When we induced the expression of ABCA1
and ApoE through the activation of LXRs, we observed a signifi-684 Neuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc.cant enhancement of Ab clearance in wild-type cells; however,
this effect was substantially diminished in microglia from
Abca1 null animals (Figures 5B and 5C). LXR agonist treatment
resulted in induction of cellular ABCA1 and ApoE levels in a geno-
type-related manner, providing an internal control for LXR action.
These data demonstrate that ABCA1 acts to facilitate soluble Ab
clearance through mechanisms that are reliant upon apolipopro-
tein function and are subject to regulation by LXR agonists,
supporting the conclusion that lipidated forms of ApoE act to
facilitate intracellular Ab degradation by microglia.
ApoE Lipidation Status Influences the Extracellular
Degradation of Ab by IDE
The proteolytic degradation of Ab occurs both within cells and
in the extracellular milieu of the brain. Ab peptides are degraded
in the extracellular space and interstitial fluid of the brain princi-
pally by IDE, with minor contributions by other secreted protein-
ases (Qiu and Folstein, 2006). IDE has been reported to be se-
creted by microglia and to degrade soluble Ab (Qiu et al.,
1998), but it is unknown whether astrocytes act similarly. We first
verified that active IDE is synthesized and secreted by astrocytes
(Figure S4), and, upon addition of soluble Ab to the astrocyte-
conditioned medium, the Ab peptide is efficiently degraded (Fig-
ures 6A and 6B). The degradation of Ab was inhibited in the
Neuron
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BV2 microglia (A) or primary microglia from wild-type mice (B) were pretreated with DMSO or 1 mM GW3965 for 18 hr. The cells were then incubated with 2 mg/ml
Ab42 in the presence or absence of 20mg/ml ApoA-I for 3 hr or 24 hr, respectively. Cellular lysates were subjected to SDS-PAGE and western blotted for ABCA1,
ApoE, Ab, and b-actin or b-tubulin. The levels of Abwere normalized to b-actin or b-tubulin as loading controls. Relative intracellular Ab levels were quantified from
three independent experiments (mean ± SEM, **p < 0.01, ***p < 0.001, ##p < 0.01). (C) Primary microglia from wild-type mice were pretreated with DMSO, 1 mM
GW3965, or 1 mM T0901317 for 18 hr. The cells were then incubated with 2 mg/ml Ab42 in the presence or absence of 5 mg/ml purified human plasma ApoE for
24 hr. Intracellular Ab levels were quantified using ELISA for Ab42 and normalized to total protein. The data represent the outcome of four independent exper-
iments (mean ± SEM, ***p < 0.001, #p < 0.05, ###p < 0.001).presence of insulin, a competitive inhibitor of IDE, supporting the
notion that IDE (and/or related proteinases whose activity is also
inhibited by insulin) was responsible for Ab proteolysis in the
conditioned media.
Next, we tested whether ApoE promoted the degradation of
soluble Ab extracellularly by IDE in the same fashion that we
observed within microglia and whether the ABCA1-dependent
lipidation was important for this process. Astrocytes are the pre-
dominant source of ApoE in the brain and secrete it into the extra-
cellular space; thus, we employed conditioned medium from
these cells containing both ApoE and IDE and evaluated Ab deg-
radation. Soluble Ab42 was added to astrocyte-conditioned me-
dium, and Ab levels were measured 24 hr later. We found that
conditioned medium from wild-type astrocytes efficiently de-
graded Ab (Figure 6C). However, conditioned medium obtained
from Abca1/ astrocytes that contain poorly lipidated forms of
ApoE (Figure S1) exhibited significantly higher (4-fold) levels of
remaining Ab measured either by western analysis (Figure 6C)
or ELISA (Figure 6D). The reduced levels of ApoE in Abca1/
conditioned media after 24 hr are consistent with previous re-
ports that suggested that the stability of ApoE is regulated by
its lipidation status (Hirsch-Reinshagen et al., 2004; Wahrle
et al., 2004). The reduced degradation of Ab is not due to differ-
ences in the levels of IDE or overall enzymatic activity in the con-
ditioned medium derived from Abca1/ compared to wild-type
astrocytes (Figure S4). These data demonstrate that the lipidation
status of ApoE regulates its stability and influences extracellular
soluble Ab proteolysis by IDE (and/or related proteinases).We then employed an in vitro assay to verify that the lipidation
status of ApoE regulated the degradation of Ab by IDE. We im-
munoprecipitated ApoE-containing HDL particles from the con-
ditioned medium of wild-type and Abca1/ astrocytes and then
incubated the particles with Ab42 in the presence of recombinant
IDE for 1 hr. Parallel samples from Apoe/ astrocytes provide
a negative control for this experiment. We found that Ab, in the
presence of nascent highly lipidated forms of ApoE derived
from wild-type animals, was more efficiently degraded by IDE.
In contrast, poorly lipidated forms of ApoE derived from
Abca1/ mice were much less effective in facilitating soluble
Ab degradation (Figure 6E). These data demonstrate that the
capacity of IDE to degrade Ab is governed by the lipidation status
of ApoE.
The LXR Agonist GW3965 Reduces Plaque Pathology
and Improves Memory in Tg2576 Mice
We investigated the effects of LXR agonist treatment on AD-re-
lated pathology in aged Tg2576 mice that overexpress hAPPswe
(Hsiao et al., 1995) and exhibit extensive deposits of Ab by 1 year
of age (Kawarabayashi et al., 2001). One-year-old Tg2576 mice
were treated orally with the LXR agonist GW3965 for 4 months.
We found that GW3965-treated animals exhibited many fewer
plaques (Figure 7A), with an 50% reduction in overall plaque
number (Figure 7B) and 67% reduction in plaque load (Figure 7C)
in the hippocampus compared with Tg2576 mice fed a control
diet. We found a corresponding 50% reduction in the levels of
total Ab40 (Figure 7D) and Ab42 (Figure 7E) peptides in the brainsNeuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc. 685
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did not affect APP expression levels or alter the levels of C-termi-
nal APP fragments (Figure 7F). Thus, drug treatment did not
significantly affect APP metabolism or Ab generation in vivo.
GW3965 administration resulted in the elevation in brain levels
of ApoE and ABCA1, demonstrating the ability of this drug to
act within the brain upon LXR target genes (Figure 7F). LXRs
have been demonstrated to exhibit robust anti-inflammatory ac-
tions in the brain (Zelcer et al., 2007), and we observed that the
LXR-mediated reduction in Ab deposition was accompanied by
Figure 4. ApoE Is Essential for Efficient
Degradation of Ab
(A) Loss ofApoe resulted in intracellular accumula-
tion of Ab. Primary microglia from wild-type or
Apoe/ mice were treated with 2 mg/ml Ab42 for
24 hr. The lysates were subjected to SDS-PAGE
and western blotted for ABCA1, ApoE, Ab, and
b-tubulin as a loading control. Blots shown are
representative of three independent experiments.
(B) Intracellular Ab levels were quantified using
ELISA for Ab42 and normalized to total protein.
The data represent the outcome of five indepen-
dent experiments (mean ± SEM, **p < 0.01).
(C) Exogenous ApoE rescued the Ab degrading
deficiency in Apoe/ microglia. Primary microglia
from Apoe/ mice were incubated with 2 mg/ml
Ab42 in the absence or presence of 1 mg/ml
ApoE for an additional 24 hr. Intracellular Ab42
levels were quantified using ELISA and the
data normalized to total protein (mean ± SEM,
***p < 0.001).
(D) ApoE is required for the LXR-mediated effect
on Ab degradation. Primary microglia from
Apoe/ mice were pretreated with DMSO or
1 mM GW3965 for 18 hr. The cells were then incu-
bated with 2 mg/ml Ab42 for an additional 24 hr. In-
tracellular Ab42 levels were quantified using ELISA
and data normalized to total protein.
(E) Native ApoE particles enhanced Ab degrada-
tion in an isoform-dependent manner. Primary microglia from Apoe/ mice were treated with 2 mg/ml Ab42 in the absence or the presence of 200 ng/ml purified
ApoE-containing native HDL particles isolated from immortalized astrocytes expressing the human ApoE isoforms for 24 hr. The levels of remaining intracellular
Ab were quantified using ELISA for Ab42. The data represent the outcome of four independent experiments (mean ± SEM, **p < 0.01, ***p < 0.001, #p < 0.05).
Figure 5. ABCA1 Influences the Intracellular Degradation of Ab by Microglia
(A) Loss ofAbca1 impairs Ab degradation in primary microglia. Primary microglia fromAbca1+/+,Abca1+/, andAbca1/mice were treated with 2 mg/ml Ab42 for
24 hr. The cellular levels of Ab42 were measured in lysates by ELISA. The data were normalized to total protein and represent the outcome of five independent
experiments.
(B) Primary microglia fromAbca1+/+ andAbca1/mice were pretreated with DMSO or 1 mM GW3965 for 18 hr. The cells were then incubated with 2 mg/ml Ab42 in
the presence or absence of 1 mM GW3965 for 24 hr. Cellular lysates were subjected to SDS-PAGE and western blotted for ABCA1, ApoE, Ab, and b-actin.
Representative blots from three independent experiments are shown.
(C) Primary microglia from Abca1+/+ and Abca1/ mice were treated as above. Intracellular Ab levels were quantified using ELISA for Ab42 and normalized to
total protein. The data represent the outcome of six independent experiments (mean ± SEM, *p < 0.05, ***p < 0.001).686 Neuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc.
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ApoE
(A) Astrocyte-conditioned medium degrades soluble Ab by IDE and related proteinases. Astrocyte-conditioned medium from wild-type mice was incubated with
Ab42 in the presence or absence of 10 mM insulin for 24 hr. The samples were then subjected to SDS-PAGE and western blotted for ApoE and Ab.
(B) After 24 hr, the samples were analyzed for Ab42 using ELISA. The data represent the outcome of three independent experiments (mean ± SEM, **p < 0.01).
(C) Lipidation status of ApoE regulates Ab degradation in astrocyte-conditioned medium. Conditioned media from astrocytes derived from Abca1+/+, Abca1+/,
andAbca1/mice were incubated with 1 mg/ml Ab42 for 0 or 24 hr and the reaction mixtures were subjected to SDS-PAGE and western blotted for ApoE and Ab.
Representative blots from three independent experiments are shown.
(D) The amount of Ab42 remaining in the medium after 24 hr was quantified using ELISA. The data represent the outcome of three independent experiments
(mean ± SEM, **p < 0.01, ##p < 0.01).
(E) ApoE-containing HDL particles promote Ab degradation by recombinant IDE. ApoE-containing HDL particles were collected from astrocyte-conditioned
medium derived from wild-type, Abca1/, and Apoe/ mice by immunoprecipitation, and the complexes were incubated with 500 ng/ml recombinant IDE
and 2mg/ml Ab42 for 1 hr. The reaction mixtures were then resolved by SDS-PAGE and western blotted for IDE, ApoE, and Ab.a corresponding decrease in the number of activated, plaque-as-
sociated microglia and interleukin-6 mRNA levels (Figures S5A–
S5D). These data demonstrate that LXR activation results in re-
duced Ab deposition in an animal model of AD that is postulated
to occur through facilitating Ab clearance from the brain.
Finally, as preplaque Tg2576 mice have been shown to display
an Ab-dependent deficit in contextual memory (Jacobsen et al.,
2006), we examined the effects of GW3965 on memory pro-
cesses in these animals. Twenty-week-old Tg2576 mice were
treated orally for 6 days with GW3965 or vehicle and trained
and tested for contextual memory following the contextual fear
conditioning procedure. Treatment of Tg2576 mice with
GW3965 resulted in significantly improved contextual memory
scores that were not significantly different from those observed
in the wild-type animals (Figure 8). No effect of GW3965 treat-
ment was observed in wild-type animals. Together, these results
demonstrated that LXR activation not only ameliorates amyloid
plaque pathology and neuroinflammation but also improves the
memory in an animal model of AD.
DISCUSSION
Sporadic, late-onset AD is the most common form of the dis-
ease, and the only established genetic risk factor is possession
of one or more APOE4 alleles (Roses, 1996; Tanzi and Bertram,
2005). It remains unclear how ApoE participates in disease path-
ogenesis. ApoE is implicated as a critical regulator of the propen-sity of Ab to be deposited within the brain. Examination of APP-
expressing mice lacking the murine apoe gene failed to develop
compact amyloid plaques but exhibited elevated levels of Ab
peptides within the brain (Bales et al., 1997). Strikingly, when hu-
man ApoE isoforms were expressed in these animals, there was
a delay in the onset of plaque deposition and a significant reduc-
tion in plaque burden that was isoform specific (E2 > E3 > E4) and
gene-dose dependent (DeMattos et al., 2004). These data sug-
gested that ApoE influenced Ab deposition and promoted Ab
clearance, with the ApoE4 isoform being less effective than other
isoforms in facilitating removal of these peptides from the brain.
Age-related impairment of Ab homeostatic mechanisms has
been postulated to be a critical determinant of disease risk. Ab
peptides are normally generated at high levels in the brain
(8%/hour) and are cleared at an equivalent rate in both humans
and mice (Bateman et al., 2006). Thus, even modest reductions
in clearance of soluble Ab could result in elevated levels of Ab
peptides and ultimately their deposition within the brain. The
clearance of Ab peptides from the brain is accomplished by their
proteolytic degradation within the brain and by their efflux
through the blood-brain barrier (Tanzi et al., 2004). ApoE has
been postulated to facilitate Ab clearance across the blood-brain
barrier, owing to its ability to form complexes with Ab and to be
exported to the peripheral circulation via LRP1 in vascular endo-
thelial cells (Deane et al., 2004). However, a recent quantitative
analysis has revealed that ApoE:Ab complexes are inefficiently
cleared through this mechanism, and lipidated forms of ApoENeuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc. 687
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ApoE Promotes the Proteolytic Degradation of AbFigure 7. LXR Agonist Treatment Reduces Ab Levels and Ameliorates Plaque Burden in Tg2576 Mice
(A) Aged Tg2576 mice (12-month-old) or genetically similar controls were treated for 4 months with normal chow or chow containing GW3965 (120 mg/kg, 33 mg/
kg/day). Ab plaque burden was monitored by 6E10 staining in the hippocampus. Plaque number and plaque area were quantified in (B) and (C), respectively (n = 5,
mean ± SEM, *p < 0.05, **p < 0.01). The levels of Ab40 (D) and Ab42 (E) were quantified using ELISA (mean ± SEM, *p < 0.05). (F) The levels of full-length APP, C99
C-terminal fragment, total Ab, ABCA1, and ApoE were monitored by western analysis. The results were normalized to b-actin (n = 5, mean ± SEM, *p < 0.05, **p <
0.01). Quantification of the data is shown under the western blots.are not significantly trafficked by this process (Bell et al., 2007).
These finding suggest that ApoE promotes Ab clearance from
the brain principally through intrinsic proteolytic mechanisms.
The physiological importance of intrinsic Ab proteolysis has
been demonstrated in vivo. Mice in which Nep or Ide have
been genetically inactivated exhibit higher Ab levels and en-
hanced plaque deposition in the brain (Farris et al., 2003, 2007;
Iwata et al., 2001).
The present study documents a mechanism through which
ApoE stimulates the degradation of soluble Ab peptides within
the brain. We show that ApoE facilitates the proteolytic degrada-
tion of soluble Ab, both within microglia and in the extracellular
milieu, through the action of two distinct classes of proteinases.
Significantly, the proteolysis of Ab is dramatically enhanced in
the presence of lipidated apolipoproteins (Figure 9). The transfer
of lipids to ApoE is accomplished principally by ABCA1, and sev-
eral recent studies have provided direct evidence for the func-
tional importance of this process in Ab homeostasis. Three inde-
pendent studies in different hAPP mice lacking the Abca1 gene688 Neuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc.have demonstrated that the absence of Abca1 results in low
levels of poorly lipidated ApoE in the brain. Importantly, Abca1
inactivation did not affect APP processing or Ab production.
However, these animals exhibited much greater Ab plaque loads
and higher levels of insoluble forms of ApoE, reflective of the co-
deposition of these molecules (Hirsch-Reinshagen et al., 2005;
Koldamova et al., 2005a; Wahrle et al., 2005). Thus, the dominant
effect of Abca1 inactivation in vivo is to impair Ab clearance,
without a significant impact on Ab synthesis.
We demonstrate that the proteolytic degradation of Ab is stim-
ulated by LXR agonist treatment and is reliant upon the LXR
target genes, Apoe and Abca1. ApoE secreted from wild-type
glia is fully lipidated (Hirsch-Reinshagen et al., 2004; Wahrle
et al., 2004) and enables soluble Ab to be efficiently degraded
by proteinases. Our findings are consistent with the previous re-
port that Ab present within lipidated ApoE:Ab complexes iso-
lated from human brains was more susceptible to proteolytic
degradation than with purified ApoE, which is poorly lipidated
(Russo et al., 1998). We favor a model in which ApoE interacts
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ApoE Promotes the Proteolytic Degradation of Abwith Ab, acting to chaperone its proteolysis. However, we cannot
exclude the possibility that enhanced intracellular proteolytic
degradation of Ab might arise from HDL-mediated changes in
cellular membrane lipid composition, as Abca1 null microglia re-
tain a partial response to the LXR agonist GW3965. Indeed, LXR
has been demonstrated to induce the expression of other cho-
lesterol transporters and apolipoproteins involved in HDL metab-
olism, such as Abcg1 and Apod, respectively (Zelcer et al.,
2007). The ApoE-dependent soluble Ab clearance mechanisms
reported here appear to be distinct from those that occur in adult
astrocytes, which involve the ApoE receptor LRP1 and depos-
ited forms of Ab (Koistinaho et al., 2004).
Much of the initial interest in LXR action centered on the roles
of these receptors and ABCA1 in neuronal APP processing and
Ab generation. LXR activation in cell culture models yielded con-
flicting data and was shown to either increase (Fukumoto et al.,
2002) or suppress Ab production (Burns et al., 2006; Koldamova
et al., 2003; Sun et al., 2003). Subsequent studies in mice have
uniformly found that LXR agonist treatment of wild-type (Burns
et al., 2006) or young APP-expressing mice (Koldamova et al.,
2005b; Lefterov et al., 2007; Riddell et al., 2007) resulted in a sig-
nificant decrease in brain Ab levels, and we report similar results
in aged Tg2576 mice treated with GW3965. Moreover, we have
recently reported that hAPP mice in which either Nrlh3 or Nrlh2
have been knocked out exhibit a significant increase in Ab pla-
que pathology (Zelcer et al., 2007), consistent with the view
that LXR activation facilitates Ab clearance from the brain. These
recent studies also found that LXRs inhibited the microglia-me-
diated inflammatory response and inflammatory gene expres-
sion, owing to their ability to functionally inactivate the promoters
of proinflammatory genes (Zelcer and Tontonoz, 2006). We have
reproduced this finding in aged Tg2576 mice with existing pla-
que pathology. Thus, LXRs can act to ameliorate AD pathogen-
esis through their action on both Ab clearance and suppression
of the plaque-related inflammatory response.
The behavioral impairment associated with overexpression of
hAPP has been postulated to be due to elevated levels of soluble
forms of Ab within the brain (Comery et al., 2005; Riddell et al.,
Figure 8. GW3965 Significantly Improves Contextual Memory in
Tg2576 Mice
Tg2576 or wild-type mice (20-week-old) were orally treated with vehicle or
50 mg/kg/day of GW3965 for 6 days and subjected to contextual memory as-
sessment as outlined in the Experimental Procedures. Treatment of the LXR
agonist improved hippocampal-dependent contextual memory in the hetero-
zygous Tg2576 mice (n = 11, mean ± SEM, *p < 0.05). No significant effect
of treatment was observed in contextual memory in the wild-type littermate
control mice. No significant effect of genotype was observed in hippocam-
pal-independent cue conditioning (data not shown).2007; Walsh and Selkoe, 2004). We found that treatment of
Tg2576 mice with the LXR agonist GW3965 resulted in a dra-
matic improvement in contextual memory, and this finding,
too, is consistent with the LXR-stimulated Ab clearance.
In summary, we provide data documenting a previously unap-
preciated action of ApoE in facilitating the proteolytic clearance
of Ab peptides from the brain. We postulate that ApoE acts both
within microglia and in the extracellular space to affect the clear-
ance of Ab through promoting its proteolysis by at least two dis-
tinct classes of proteinases. Importantly, the ApoE4 isoform,
which is associated with increased risk for AD, exhibits an
impaired ability to promote Ab proteolysis compared to the
ApoE2 and ApoE3 isoforms. There is a remarkable correspon-
dence in the effects of LXR activation and Abca1 inactivation
(or overexpression) in animal models of AD that support an
essential role for the lipidation of ApoE in removing soluble Ab
from the brain. The present study provides a mechanistic expla-
nation of both the effects of Abca1 inactivation (or overexpres-
sion; Wahrle et al., 2008) and the Nrlh3 and Nrlh2 knockouts
(Zelcer et al., 2007) on Ab plaque pathology in animal models
of AD. Our data suggest that therapeutic agents that increase
the levels of lipidated forms of ApoE, including LXR agonists,
represent a potentially efficacious therapy for AD.
EXPERIMENTAL PROCEDURES
Animals
Tg2576 mice or wild-type littermates (five animals/group), 12 months of age,
were fed the AIN-76A standard rodent diet alone or containing GW3965
(120 mg/kg; 33 mg/kg/day) ad libitum for 4 months. The animals were
Figure 9. ApoE and Its Lipidation Status Regulate the Proteolytic
Degradation of Soluble Ab
The level of soluble Ab is homeostatically controlled by its production by neu-
rons and its subsequent clearance. Soluble Ab can be cleared by proteolytic
enzymes including NEP and IDE acting both intracellularly and extracellularly.
ApoE is principally synthesized and secreted by glia. The lipid transporter
ABCA1 mediates the lipidation of ApoE. Liver X receptors regulate the expres-
sion of both ABCA1 and ApoE, and their activation results in increased levels of
lipidated ApoE. The degradation of soluble Ab both intracellularly and extracel-
lularly is enhanced by increasing ApoE and its lipidation.Neuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc. 689
Neuron
ApoE Promotes the Proteolytic Degradation of Absacrificed, and the right hemispheres were fixed and processed for immuno-
histochemical analysis. The left hemispheres were snap-frozen on dry ice
and subject to serial extraction of total RNA, DNA, and protein. Wild-type
mice (C57BL/6), Apoe null mice (B6129P2-Apoetm1Unc/J), and Abca1 het-
erozygote mice (DBA/1-Abca1tm1Jdm/J) were obtained from Jackson Labo-
ratory (Bar Harbor, ME). Abca1+/+, Abca1+/, and Abca1/ mice were bred
from Abca1 heterozygote mice (DBA/1-Abca1tm1Jdm/J). Tg2576 mice were
maintained by crossing to B6SJLF1/J animals.
Cell Culture
BV2 microglia were maintained in DMEM containing 2% FBS. Primary micro-
glia and astrocytes were prepared from P0–P3 mice, and purified microglia
and astrocyte cultures were obtained as previously described (Koenigsknecht
and Landreth, 2004; Zander et al., 2002). Immortalized astrocytes derived from
human APOE knockin mice (Morikawa et al., 2005) were maintained in DMEM
containing 10% FBS, 500 mg/ml G418, and 1 mM sodium pyruvate.
Preparation of Ab Peptides
Ab42 or Ab40 lyophilized powder (American Peptide Company, Sunnyvale,
CA) was dissolved to a final concentration of 1 mg/ml in DMSO and stored
at 80C until use. Fluorescently labeled peptides were prepared by first dis-
solving the peptides to a concentration of 2 mmol/l in sterile H2O. The Ab42
was then labeled with Cy3 (Amersham Biosciences, Pittsburgh, PA) or Alexa
488 fluorophores (Invitrogen, Carlsbad, CA) using the manufacturer’s protocol.
The Ab42 reaction mixture was allowed to fibrillize at 37C overnight, after
which unincorporated dyes were removed by ultracentrifugation at 4C. The
pellet was then resuspended in DMSO, sonicated, and ultracentrifuged. This
was subsequently repeated until the fAb was solubilized in DMSO. The super-
natant contains the operationally defined ‘‘soluble Ab,’’ which exhibits an elec-
trophoretic mobility corresponding to 4 kDa on SDS-PAGE and is predicted
to consist of primarily monomeric and small oligomeric species (Shen and
Murphy, 1995).
Western Blot Analysis
Protein concentrations of cell lysates or brain extracts were measured using
the BCA method (Pierce, Rockford, IL). For western blot analysis of Ab,
10%–20% tricine gels or 4%–15% bis-tris gels (Invitrogen, Carlsbad, CA)
were used. The following primary antibodies were used: anti-human Ab,
6E10 (Covance, Dedham, MA); anti-ApoE (Calbiochem, San Diego, CA);
anti-b-actin; anti-b-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA);
anti-ABCA1 (Novus Biologicals, Littleton, CO); anti-APP CTF (Millipore,
Billerica, MA).
Immunohistochemistry and Image Analysis
Postfixed hemispheres were sectioned sagittally into 10 mm sections using
a cryostat. Sections were mounted, air-dried, and then stored at 4C until
use. For Ab immunohistochemistry, sections (three per mouse, about 1.2–
1.5 mm from the midline, spaced 0.1 mm apart from each other) were incu-
bated in 70% formic acid for 3 min, and the endogenous tissue peroxidase ac-
tivity was quenched by incubation with 1% peroxide in methanol for 10 min.
Sections were then microwaved in distilled water for 3 min and then incubated
with blocking solution (5% normal goat serum and 0.1% Triton X-100 in PBS)
for 1 hr. Sections were incubated with primary antibody in the blocking solution
overnight at 4C. The antigens were detected by secondary antibodies using
standard ABC-DAB methods. Sections were counterstained with hematoxylin.
The 6E10 antibody against human Ab was used to stain Ab plaques. Images
were analyzed using Image Pro-Plus software (Media Cybernetics, Silver
Spring, MD).
Ab ELISAs
Ab40 and Ab42 ELISAs were performed using commercial kits (Invitrogen,
Carlsbad, California) following the manufacturer’s instructions. Alternatively,
Ab1-x, Ab40, or Ab42 ELISAs were performed using 6E10 as the capture anti-
body and monoclonal 4G8, anti-Ab40, or anti-Ab42 HRP-conjugated anti-
bodies (Covance, Dedham, MA) as the detection antibodies. Synthetic Ab40
or Ab42 was used to generate a standard curve for each experiment. The
plates were developed using the TMB substrate kit (Pierce, Rockford, IL),690 Neuron 58, 681–693, June 12, 2008 ª2008 Elsevier Inc.and the reaction was stopped by addition of equal volume of 1 M HCl. The
results were read using a Spectramax colorimetric plate reader (Molecular
Devices, Sunnyvale, CA).
Conditioned Media Harvesting
Confluent primary astrocytes were washed twice with PBS (pH 7.4) and incu-
bated with fresh serum-free F12-DMEM media for 24 hr. Immortalized astro-
cytes were washed twice with PBS (pH7.4) and incubated with fresh serum-
free DMEM supplemented with 1 mM sodium pyruvate. Conditioned media
were collected and sterilized by filtering through 0.22 mm filters.
Flow Cytometry
BV2 or primary microglia were incubated with 2 mg/ml Alexa 488-labeled Ab42
in serum-free DMEM or F12 DMEM, respectively, in the presence of 10 mg/ml
BSA for 3 hr, washed extensively with PBS, and fixed with 4% paraformalde-
hyde for 5 min. Cells were washed again with PBS and collected for flow cy-
tometry using a Beckman-Coulter XL flow cytometer. The total amount of Ab
internalized was determined by fluorescent intensity of Alexa 488 as measured
by flow cytometry.
Live Cell Imaging
For live cell imaging, microglial BV-2 cells were plated overnight in DMEM
containing 2% FBS on Delta T tissue culture plates. Cells were incubated
with 2 mg/ml Cy3-Ab and 100 nmol/l Lysotracker Green DND-26 (Invitrogen,
Carlsbad, CA) in serum-free DMEM containing 10 mg/ml BSA and imaged
using a Zeiss LSM 510 confocal microscope.
Intracellular Ab Clearance
BV2 or primary mouse microglia cells were incubated with DMSO or 1 mmol/l
GW3965 for 18 hr at 37C. Cells were then treated with 2 mg/ml soluble Ab42 in
serum-free medium containing 10 mg/ml BSA for 3 hr or 24 hr, respectively, in
the presence or absence of drug. For experiments using apolipoproteins, pu-
rified human HDL ApoA-I (Sigma, Saint Louis, MO), purified human plasma
ApoE (rPeptide, Athens, GA), native ApoE2, ApoE3, or ApoE4 particles were
applied at the same time as soluble Ab42. Ab42 levels in the cell lysates
were determined by immunoblotting with the anti-Ab antibody 6E10. Briefly,
cells were extensively washed with PBS to ensure the removal of Ab, which
is attached to the cell surface. Cells were then lysed in ice-cold RIPA buffer
(Upstate Biotechnology, Lake Placid, NY), sonicated briefly, then collected
by centrifugation at 13,000 rpm at 4C for 15 min. The samples were resolved
by 4%–15% bis-tris SDS-PAGE. ABCA1, ApoE (for positive controls), and b-
actin or b-tubulin levels (for loading controls) in the cell lysates were measured
by western blot. For ELISA measurements, cells were treated similarly,
washed with PBS, and lysed in 1% SDS. Ab42 levels were measured using
ELISA and normalized to total protein.
Ab Degradation in Astrocyte-Conditioned Medium
Conditioned media from Abca1+/+,Abca1+/, and Abca1/ astrocyte cultures
were incubated with 1 mg/ml Ab42 for 0 or 24 hr. Ab42 in the media was
assessed using western analysis or ELISA.
In Vitro IDE Assay
ApoE-containing HDL particles were immunoprecipitated from the condi-
tioned medium using the anti-ApoE antibody. Recombinant (500 ng/ml) IDE
(R&D Systems, Minneapolis, MN) was incubated with 2 mg/ml Ab42 for 1 hr
in the presence of ApoE containing HDL particles. The samples were resolved
by 4%–15% bis-tris SDS-PAGE. The levels of IDE, ApoE, and Ab were moni-
tored using western analysis.
Contextual Fear Conditioning Studies
Following 6 days of treatment by oral gavage with 50 mg/kg/day GW3965 or ve-
hicle, 20-week-old Tg2576 mice (n = 11/genotype/treatment) were trained and
tested on 2 consecutive days as described previously (Comery et al., 2005).
Statistical Analysis
To compare differences between the experimental groups, two-tailed t test
or one-way analysis of variance (ANOVA) followed by the Tukey-Kramer
Neuron
ApoE Promotes the Proteolytic Degradation of Abmultiple-comparison test was performed using GraphPad Prizm software
(GraphPad Software, San Diego, CA). Contextual memory was analyzed using
a two-way ANOVA and post hoc pairwise comparison made using SAS Statis-
tical Software (SAS Institute, Cary, NC).
SUPPLEMENTAL DATA
The Supplemental Data for this article can be found online at http://www.
neuron.org/cgi/content/full/58/5/681/DC1/.
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